🇺🇸 FDA
Pipeline program

BAX 326 (Recombinant factor IX)

251001

Phase 3 mab completed

Quick answer

BAX 326 (Recombinant factor IX) for Hemophilia B is a Phase 3 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hemophilia B
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials